Ebola outbreak on track to be deadliest ever, WHO chief says
Ebola Outbreak on Track to Be Deadliest Ever, WHO Warns
Ninoda.com – The Ebola outbreak on track to be the deadliest in recorded history, according to the World Health Organization's director-general Tedros Adhanom Ghebreyesus. This ongoing crisis in the Democratic Republic of Congo is progressing at an alarming rate that could surpass the devastating 2014-2016 epidemic, which claimed more than 11,000 lives across multiple countries worldwide.
Since the World Health Organization officially announced this current wave on May 15, health authorities have documented at least 4,300 infections and over 2,000 deaths. Officials expressed cautious optimism on Wednesday that they could control the disease's expansion within three months, though they emphasized this goal means managing transmission rather than completely eradicating the outbreak.
Why This Outbreak Is Different
While the epidemic received formal declaration in May, experts now believe the virus began circulating at least three months earlier. Dr. Mohamed Janabi, who leads WHO's African operations, provided crucial insight during a press briefing held in Bunia, a city situated near the outbreak's epicenter in eastern Congo.
We are chasing the virus, the virus is ahead of us.
Janabi referenced epidemiological studies indicating that transmission started in February, with early cases frequently misidentified as either typhoid fever or malaria. This diagnostic delay has complicated containment efforts significantly, allowing the disease to spread more widely than initially anticipated.
A Rare and Challenging Strain
The 2026 crisis involves the Bundibugyo variant of Ebola, a less common form that has triggered only two documented outbreaks previously—in 2007 and 2012. Unlike other strains, this particular species lacks both an approved vaccine and recognized therapeutic treatments, making it particularly dangerous.
Compounding the difficulty of managing the epidemic is persistent regional instability surrounding the eastern DRC location where the outbreak originated. These security challenges have limited health workers' ability to reach patients, with Janabi noting that only approximately 30 percent of infected individuals are currently receiving adequate care.
Understanding Ebola's Impact
Ebola remains a rare but highly fatal viral infection. After an incubation period ranging from two to 21 days, patients experience sudden onset of symptoms resembling influenza or malaria, including fatigue, headaches, and elevated temperature. As the illness advances, severe vomiting and diarrhea typically develop, potentially culminating in multi-organ failure. The pathogen transmits between people through direct contact with contaminated bodily fluids like blood or vomit.
Developing Solutions and Hope
Progress is being made on countermeasures. Britain's medicines regulatory body, the MHRA, has authorized the commencement of human trials for a Bundibugyo-specific vaccine. This experimental injection utilizes technology developed by Oxford University researchers, the same platform that powered the Oxford-AstraZeneca coronavirus vaccine.
Additionally, three other organizations are pursuing distinct vaccine candidates for this strain, though none have yet progressed to clinical testing. The WHO is simultaneously funding a separate trial within Congo to evaluate whether two established antiviral medications can enhance patient survival outcomes.
Frequently Asked Questions
How does the 2026 Ebola outbreak compare to previous epidemics? This outbreak involves the rarer Bundibugyo strain and lacks both a vaccine and approved treatments, unlike the 2014-2016 epidemic which involved the more common Zaire strain.
Why was the outbreak detected late? Early cases were frequently misdiagnosed as typhoid fever or malaria, with transmission actually beginning in February before the official May 15 declaration.
What is being done to develop treatments? Multiple organizations are developing vaccine candidates, while Britain's MHRA has authorized human trials for a Bundibugyo-specific vaccine using Oxford University technology.
How many people are receiving care? Due to security challenges in eastern Congo, only approximately 30 percent of infected individuals are currently receiving adequate medical attention.
As health workers continue their efforts on the ground, the international community watches closely to see whether coordinated action can prevent this outbreak from becoming the deadliest in Ebola's history.